Twenty-one RCTs (n=8,641 patients) were included in the review; 4,320 patients allocated to bare-metal stents and 4,321 patients allocated to drug-eluting stents. The sample sizes ranged from 42 to 1,197.
Mean in-stent late loss ranged from -0.01 to 0.63 mm in drug-eluting stent patients, and 0.63 to 1.09 mm in bare-metal stent patients. Δin-stent late loss ranged from 0.00 to 1.04 mm. Number-needed-to-treat for new target lesion revascularisation procedures ranged from four to 22 patients. No publication bias was reported. Heterogeneity was not reported.
There was a significant relationship between mean in-stent late loss in patients randomised to drug-eluting stent and number-needed-to-treat for target lesion revascularisation (0.62 mm, 95% confidence interval (CI) for β: 5.8 to 31.0; p=0.007), such that a 0.1 mm increase in mean in-stent late loss-drug-eluting stent was associated with a 1.8 increase in number-needed-to-treat for target lesion revascularisation.
There was also a significant association between Δin-stent late loss with the number-needed-to-treat for target lesion revascularisation (0.61 mm, 95% CI for β: -20.1 to -3.6; p=0.008), such that a 0.1 mm reduction in Δin-stent late loss was associated with a 1.2 decrease in mean number-needed-to-treat for target lesion revascularisation.
Additional outcomes were also reported.